NR1H4 and hyperandrogenism: These include the reorganization of the SCFAs network, activation of the BA-FXR signaling axis, and inhibition of the LPS-inflammation axis, which collectively target hyperandrogenism, insulin resistance, and ovulatory dysfunction in a tissue-specific manner.